CUREBOUND

2022 ANNUAL REPORT

TABLE OF CONTENTS

Curebound Friends,

As we continue charging into 2023 and building upon the foundation established last year, it is with tremendous gratitude, appreciation and pride that we share Curebound's first annual report with you. For Curebound, 2022 was about building momentum. Thanks to your support, we continue to mobilize the San Diego community and build momentum across every dimension of the organization to accelerate cancer research into cures for patients. Year in review:

- On March 30, we hosted Curebound's Road to Discovery Event at Alexandria's Farmer & the SeaHorse where we heard from Curebound-funded physician Ramez Eskander, MD from UC San Diego Health, Lev Becker, PhD from University of Chicago & Founder of Onchilles Bio-Pharma, and Rick Valencia share a personal, harrowing, and insightful conversation about what it's like to experience a complex ovarian cancer alongside recent advancements in women's gynecological cancers.
- On April 9, thousands of passionate fundraisers, cancer fighters and hundreds of teams returned to Petco Park for the first in-person Padres Pedal the Cause since 2019. The day was filled with passion, joy, and inspiration.
- On June 16, we celebrated a World Without Cancer Day by capturing hundreds of stories from families across San Diego who shared what a world without cancer looked like to them. Later that evening we unveiled the largest check in Padres Pedal history for a total of $3.2 million.
- On September 20, cancer researchers, biotech leaders, and members of the life science community kicked off a new Curebound series--Curebound Connects—where Ben Cravatt PhD from Scripps Research shared guidance and lessons learned on how to translate major scientific discoveries into effective biotech companies that can carry products through to commercial stages and on to patients.
- On Friday November 4, Alicia Keys and the San Diego Symphony performed an extraordinary collaboration at our first ever Concert for Cures at the Rady Shell to a spellbound audience. All who attended will surely never forget hearing Alicia swap in "Curebound" for "New York," in her hit Empire State of Mind and sharing how her Grandma fought cancer.
- On December 7, we shined a spotlight on Curebound-funded research teams at an intimate and engaging poster session featuring 14 teams that discussed progress and outcomes made possible by Curebound funding.

Days before the poster session, I had the opportunity to celebrate the life of a passionate Curebound Founding Board Member, Jay Levitt, who lost a long and exhausting battle with cancer. Through the beautifully orchestrated remembrance, friends and strangers from across the country came together over laughs, smiles, and body-aching tears of loss over the leader we were celebrating. Jay was originally told he had 6 months to live yet went on to criss-cross the country and globe for 3.5 years pursuing every innovation on the standard of care he could find to stretch the number of days he could spend with his wife, daughter, and enormous circle of family and friends. It was in that time where Jay helped found Curebound and dedicate his final months advancing his belief in collaboration to break scientific barriers.

Let's honor Jay's passion and let his journey remind us that every dollar invested in collaborative cancer research can translate to one more day.

Thank you for your partnership and I look forward to seeing you soon.
All the best,

Anne Marbarger
Curebound CEO

MISSION

Mobilize San Diego to accelerate cures for cancer in our lifetime.

UC San Diego Health

salk
Where cures begin.

Sanford Burnham Prebys

Rady Children's

La Jolla Institute
FOR IMMUNOLOGY

Scripps Research

UNITED WE CURE

Curebound unites San Diego's top institutions in a collaborative effort to accelerate cancer research into cures.

Founded upon a deeply held belief that cures are possible, we believe that the next decade will be critical to the development of sophisticated, individualized cancer treatment and the largest opportunity ever seen to advance the way we treat, and ultimately cure cancer. All of this is possible in San Diego. San Diego is recognized as one of the largest and fastest growing life science communities in the country and uniquely positioned to be a global center for cancer research, innovation and care. The city is home to three NCI-designated cancer centers, internationally recognized biotech research institutions, top clinical care hospitals and nearly 1000 life science companies. Headquartered amongst this powerful scientific hub, Curebound is the catalyst to bring these resources together to drive this work faster and further- to expedite discovery and improve the lives of patients today.

In 2021, two highly respected local cancer organizations, Padres Pedal the Cause and Immunotherapy Foundation, united to form Curebound with an initial goal to raise and invest $100+ million into collaborative cancer research in San Diego. Over the last decade, these two organizations have collectively awarded over $23 million in funding for 90 research grants that explore 20+ types of adult and pediatric cancers, including 6 pioneering clinical trials. To accelerate its impact, Curebound launched a Founder's Fund campaign in 2021, which has since raised nearly $25 million in new commitments - bringing cumulative commitments since 2013 to over $50 million.

Guided by a world-class Scientific Advisory Board, Curebound awarded twelve collaborative Discovery Grants among our research partner institutions in 2022. The first Cure Prize, a highly anticipated $1+ million grant award for innovative, groundbreaking ideas intended to improve the standard of care for deadly cancers will be awarded in early 2023.

BY THE NUMBERS

$23 MILLION
AWARDED FOR CANCER RESEARCH SINCE 2013

90
RESEARCH GRANTS FUNDED

6
TOP INSTITUTIONS WORKING TOGETHER

21
DIFFERENT TYPES OF CANCER RESEARCH FUNDED

66
ADULT CANCER PROJECTS FUNDED

24
PEDIATRIC CANCER PROJECTS FUNDED

2022 GRANTS

Curebound is dedicated to accelerating cancer cures by funding the most promising, innovative research to collaborative teams from our six research partner institutions. In 2022, we awarded $3 million in Discovery Grant funding to 12 teams for early-phase oncology research in alignment with Curebound's five scientific investment pillars:

- Prevention and diagnostic tools
- Novel approaches and new therapeutic platforms
- Immunotherapies and personalized vaccines
- Cancer equities
- Pediatric cancers

We are proud to support these exceptional research teams in their work and look forward to reporting on their progress and research outcomes in years to come.

2022 GRANTS

1.Decoding the Role of the Long Non-Coding RNA PVT1 in Medulloblastoma

Primary Investigators: Anindya Bagchi (SBP), Lukas Chavez (UCSD)
Investment Pillar: Pediatric Cancer

Abstract: Medulloblastoma (MB) is the most common malignant childhood brain tumor. This Discovery Team is focused on Group 3, which has the worst prognosis of all medulloblastomas and has few therapeutic options. To treat this deadly cancer, the Discovery Team's research has uncovered an oncogene, PVT1, that effectively eliminates the most potent protein (MYC) in the deadliest form of medulloblastoma and ultimately limits tumor growth. Recently, they have uncovered the key component (Firefox) of PVT1 that is driving the elimination of that protein. This research will investigate further why Firefox is eliminating the MYC protein and therefore inhibiting growth of medulloblastoma. Understanding why this is occurring could lead to new therapies for the deadliest form of medulloblastoma.

"Medulloblastoma is one of the dreaded childhood cancers. Our quest is to see that no child suffers from this disease. The advances on the horizon in cancer research are already making its impact and the support from Curebound will directly help us to develop cures in our lifetime so that children afflicted with this cancer can live a full, happy, and healthy lives."

-Anindya Bagchi, PhD
Sanford Burnham Prebys

2. High throughput-screen for inhibitors of pediatric ependymoma

Primary Investigators: Michael Jackson (SBP) & Lukas Chavez (UCSD)
Investment Pillar: Pediatric Cancer

Abstract: Brain and other tumors of the central-nervous system (CNS) are the most common cancers in children aged 0- 14 years in the USA. Ependymoma (EPN) is the third most common pediatric brain tumor and a leading cause of death in childhood cancer patients. This Discovery Team is focused on the most common and aggressive subgroup, posterior fossa ependymoma group A (PFA), which occurs mainly in young children and frequently leads to recurrences. In this project, the team proposes to screen patient derived PFA EPN samples with drugs already approved by the FDA for various other conditions and diseases. These compounds are safe to administer to humans and as such provide the quickest path to identifying drugs that could be rapidly deployed to ependymoma patients in the medium term. The team will prioritize drugs that can access the brain and will test for agents that are effective only against ependymoma, and not normal healthy brain cells, to avoid eventual toxicity. Once active drugs have been identified the team will also investigate their mechanisms of action. By investigating changes in gene expression after treatment we will identify specific genes and downstream pathways that are involved in cell death and survival of ependymoma cells, potentially allowing further targeting of this deadly childhood disease.

2022 GRANTS

3. Targeting tumor-associated macrophages to improve immunotherapy in neuroblastoma

Primary Investigators: Shweta Joshi (Rady), Judith Varner (UCSD)
Investment Pillar: Pediatric Cancer

Abstract: Neuroblastoma accounts for over 15% of pediatric cancer deaths and the 5-year survival rate of these patients is very low. Current therapies are clearly not effective and novel, safe therapies are needed to improve patient outcomes. This Discovery Team's preclinical research will combine two inhibitors (Syk and/or PI3K) with an immunotherapy to translate into a therapy against neuroblastoma. Prior research by this team has shown that those two inhibitors cause macrophages and T cells to mount a continued response against solid tumors. Without treatment, macrophages initially kill and destroy cancer cells but are very quickly co-opted by cancer cells to increase tumor growth and suppress tumor killing T-cells. In the end, usage of Syk and PI3k inhibitors have reversed that trend and allows for the macrophages to work with T-cells to attack tumor growth.

4. Understanding the biological and clinical role of ecDNA in neuroblastoma

Primary Investigators: Ludmil B. Alexandrov (UCSD) & Peter E. Zage (Rady)
Investment Pillar: Pediatric Cancer

Abstract: Children with aggressive neuroblastoma tumors have poor rates of survival and cure despite intensive treatment, and better clinical management is needed. Interestingly, higher copies of the MCYN gene is associated with worse overall survival from neuroblastoma.

Recently, it was shown that MYCN can be amplified both within the chromosomes or outside the chromosomes on circular DNA molecules known as extrachromosomal DNA (ecDNA). Not much is known about the biological or clinical implications of these different types of MYCN amplifications in neuroblastoma. In this project, the Discovery Team will examine large datasets from neuroblastoma patients and scrutinize their molecular patterns in regard to potential clinical associations. Moreover, the team will also screen laboratory cell line and tumor models to understand their response to commonly used drugs for treating children with aggressive neuroblastoma. Overall, the results from this study will provide a greater understanding of the biological and clinical roles of ecDNA in neuroblastoma, which may lead to improved success of neuroblastoma therapy and improved chances of survival for children with neuroblastoma.

2022 GRANTS

5. Determining the impact of regulatory mutations and dysregulated transcription factors in neuroblastoma

Investment Pillar: Pediatric Cancer
Primary Investigators: Graham McVicker (Salk), Peter Zage (UCSD/Rady)

Abstract: Neuroblastoma is a tumor of developmental origin with high incidence of metastatic disease at initial diagnosis. Comprehensive DNA sequencing of high-risk neuroblastoma has identified few clinically actionable gene mutations and precision medicine has not benefited most neuroblastoma patients. Thus, there is an urgent need to develop innovative approaches to discover novel cancer dependencies and gene targets in neuroblastoma to improve patient outcomes. The main objective of this proposal is to use new molecular experiments to discover novel genetic mutations and cancer genes and determine their impact on neuroblastoma tumorigenesis (initial growth of tumor in the body). The long-term objective of this project is to discover prognostic biomarkers and therapeutic targets for early detection and treatment of neuroblastoma.

6. Pre-clinical development of new autophagy targeting drugs for bone metastatic prostate cancer

Investment Pillar: Novel Approaches and New Therapeutics
Primary Investigators: Nicholas Cosford (SBP) & Christina Jamieson (UCSD)

Abstract: One in six men will be diagnosed with prostate cancer. While patients are being diagnosed earlier and surviving longer, a growing number of patients have gone on to develop advanced prostate cancer. The main treatment for advanced prostate cancer (PCa) is androgen pathway directed therapy (APDT). Unfortunately, patients invariably become resistant to APDT, and their cancer metastasizes - most often to bone - for which there is no cure. Also, autophagy (ATG) plays a role as a survival pathway that contributes to cancer growth, resistance, and cell dormancy. Therefore, inhibiting ATG is a novel mechanism to reduce survival of PCa resistant to APDT.

This Discovery Team will examine a class of specific ATG inhibitors in patient bone metastatic PCa cells and evaluate their ability to reduce PCa tumor burden in mouse models alone and in combination with ADPT. These studies will allow the development of a new drug therapy for the treatment of this deadly cancer and enhance patient outcomes.

2022 GRANTS

7. Therapeutics to overcome the differentiation roadblock in Myelodysplastic Syndrome (MDS)

Investment Pillar: Novel Approaches and New Therapeutics
Primary Investigators: Michael Bollong (Scripps) & Rafael Bejar (UCSD) & Arnab Chatterjee (Scripps)

Abstract: Myelodysplastic syndrome (MDS) is a pre-cancer condition involving mutations in the stem cells, which give rise to the many cell types which compose blood. These mutations cause stem cells to produce red blood cells and other cell types less efficiently, conditions called cytopenias — complications to which most MDS patients succumb. This Discovery Team has identified a class of anti-malarial medications, called Artemisinins, which overcome these mutations, making it such that stem cells can efficiently give rise to downstream blood types, thereby overcoming cytopenias. Artemisias have been used clinically to treat malaria — the discovery of which was awarded the Nobel prize in 2006 — but no Artemisinin drug is suitable for chronic oral dosing, which is required for treating MDS.

In this study, the Discovery Team will use medicinal chemistry to develop an Artemisinin derivative that can be orally dosed as therapy for this disease. Successful completion of this grant will deliver a preclinical candidate for the treatment of MDS, ready for IND-enabling safety studies, the next steps in advancing this candidate as a new drug.

8. Targeting metabolic vulnerabilities unique to pancreatic ductal adenocarcinoma

Investment Pillar: Novel Approaches and New Therapeutics
Primary Investigators: Michael Karin (UCSD), Reuben Shaw (Salk)

Abstract: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with a 5-year survival rate of 11%. Most patients die within 6 months of diagnosis from metastatic disease, but even patients who qualify for surgical resection eventually succumb to the disease. No targeted therapies are available.

Importantly, high mitochondrial content predicts poor survival, suggesting that mitochondria reducing treatments may inhibit tumor growth. Indeed, we found that an FDA-approved antibiotic called tigecycline reduces mitochondrial content and curtails PDAC metabolism and growth in preclinical models. This Discovery Team proposes to potentiate tigecycline's anti-PDAC activity by complementing it with inhibitors of an enzyme, ULK1. ULK1 is needed for the recycling and repair of PDAC mitochondria — so shutting of that enzyme would inhibit the repairment of the PDAC mitochondria that tigecycline is reducing. This novel approach, which will be tested in several preclinical models and fresh human PDAC slice cultures, should be highly effective in blunting PDAC growth by cutting off tumor energy supplies.

2022 GRANTS

9. Role of histidine phosphorylation in breast cancer invasion

Investment Pillar: Prevention and Diagnostic Tools
Primary Investigators: Tony Hunter (Salk), Jing Yang (UCSD), Kay Yeung (UCSD)

Abstract: Breast cancer is the most common type of cancer amongst women in the world and led to 684,996 deaths in 2020. New therapies are still needed to drive better outcomes for breast cancer patients. In the last three decades, the addition of a phosphate (a process called phosphorylation) to certain proteins has been the focus of intensive efforts to create new cancer therapeutics.

Phosphorylation can occur at 9 different amino acids in proteins. However, phosphorylation of only 3 of these 9 amino acids has been explored in efforts to develop cancer treatments. Phosphorylation of histidine (pHis), one of the neglected modifications, has recently been discovered to be relevant in liver cancer, but whether this is important in other types of cancer has yet to be examined in depth. Previous studies showed that a histidine kinase called NME1 suppresses metastasis in breast cancer.

Our research has shown that a pHis phosphatase called LHPP is present at higher levels in triple-negative breast cancer (TNBC), which has the worst prognosis, and currently lacks an effective treatment. Combining cutting-edge molecular biology, cell biology and genetic techniques, we will investigate if pHis, the histidine kinase NME1 and the pHis phosphatase LHPP are important for breast cancer metastasis, aiming to identify key protein targets that are regulated by histidine phosphorylation.



"This Curebound funding will play a key role in our efforts to understand the role of histidine phosphorylation in breast cancer. This is a new area of research for the group, and we hope our work can lead to identification of new drug targets to treat triple negative breast cancer, the deadliest form of the disease."

– Tony Hunter, PhD
Salk Institute

2022 GRANTS

10. Neoantigen driven eradication of immune-reprogrammed ovarian cancer
Investment Pillar: Immunotherapy and Personalized Vaccines
Primary Investigators: Dwayne Stupack (UCSD), Stephen Schoenberger (LJI), David Schlaepfer (UCSD)

Abstract: One approach to treating tumors uses intravenous therapies that boosts the immune system. This works in many cancers, however, this approach does not always work, and can fail with time as tumors find ways to avoid the immune system – even shutting off its ability to attack tumors.

In ovarian cancer, studies showed that an oral drug called a FAK inhibitor helps our ability to avoid a “shut down” of the immune system. FAK can also be combined with other immunotherapies. A second type of immunotherapy in development is a cell-based therapy that uses personalized vaccination against unique features of the tumor. While very precise, and potentially very potent, this approach is highly vulnerable to the “shut down” mechanism described previously. This proposal will test a new idea. First, we will treat tumors with the FAK drug first to block their ability to “shut down” the immune response. Then, we will use the very precise and potent personalized vaccine to attack the tumor. We will use a mouse model on ovarian cancer to determine: Which features are best to target? Can we use vaccination in a test tube and deliver the immune response to a more immune-active mouse conditioned by FAK? And, for tumors treated with chemotherapy and surgery, can we then treat them with FAK drugs together with vaccination to allow the immune system to get rid of residual disease?

2022 GRANTS

11. Development and optimization of peptide-based nanoparticle NeoAg cancer vaccines

Investment Pillar: Immunotherapy and Personalized Vaccine
Primary Investigators: Stephen Schoenberger (LJI), Ezra Cohen (UCSD), Aaron Miller (UCSD)

Abstract: This Discovery Team builds upon extensive research programs at LJI and UCSD Moores Cancer Center which have historically, in part, received funding from Padres Pedal the Cause and the Immunotherapy Foundation. In the study, the team explores Natural immune responses that protect us from viral and bacterial infections that require the coordinated activity of two subsets of T lymphocytes known as CD4+ helper" T cells and CD8+ "killer" T cells. The team has found that this same idea applies to immune responses to cancer. Specifically, that our immune response to cancer is most effective when these two T Cells are engaged by a vaccine. This concept will be integrated into our ongoing personalized cancer vaccine clinical trial.

The goal of this research is to develop a vaccine platform that will enable both CD4+ and CD8+ T cells against a patient's tumor-specific target antigens to be generated in a manner that is safe, effective, reproducible, and consistent with the regulatory and manufacturing constraints which necessarily govern what can be administered to a patient.

This work will involve testing various forms of a self-assembling peptide-based nanoparticle vaccine to identify the flanking sequences capable of insuring that a given vaccine peptide is presented to CD4+ and CD8+ T cells for recognition and the testing whether the vaccines can be targeted to the correct antigen-presenting cell to insure induction of potent therapeutic immunity. We will evaluate these in a preclinical animal model of cancer that mirrors key aspects of the human disease and, if successful, the findings from the research will be advanced for clinical testing of the nanoparticle vaccine in patients at the UCSD Moores Cancer Center.

"Our work has placed us at the cutting edge of understanding the immune response to cancer in patients and how this can be therapeutically deployed by vaccines. Our new Curebound-supported work will enable us to develop more powerful cancer vaccines capable of producing deeper and more durable immunity by simultaneously engaging both the CD4+ and CD8+ arms of a patient's mutation-specific T cell response."

- Stephen Schoenberger, PhD
La Jolla Institute for Immunology

2022 GRANTS

12. HERV env: A Targetable Surface Protein in Ovarian Cancer
Investment Pillar: Immunotherapy and Personalized Vaccine
Primary Investigators: Erica Ollmann Saphire (LJI, David Schlaepfer (UCSD)

Abstract: According to the American Cancer Society, ovarian cancer is the fifth leading cause of cancer deaths among women in the United States. However, there are few new treatments or diagnostic tools for ovarian cancer. This Discovery Team is focused on developing new tools to diagnose and treat ovarian cancer based on information derived hundreds of thousands of years ago. Before humans evolved from primates, another pandemic caused by viruses occurred. This pandemic was caused by retroviruses, which are viruses that can insert their own genetic information into the DNA of their hosts. Around 8% of human DNA is the remnant of viral genetic material from these ancient infections. These DNA remnants are called human endogenous retroviruses (HERVs). Endogenous means that these bits of viral DNA are now a stable part of our genetic make-up. These retroviral sequences were long thought to be silent 'junk' DNA, but recent research has uncovered the potential for these viral genes to start producing proteins in disease states, such as in cancer or autoimmune disease. For example, in ovarian cancer, researchers have seen that some retroviral proteins stud the surface of ovarian cancer tissues and ovarian cancer cells. In a mouse model of ovarian cancer, a monoclonal antibody treatment targeting a HERV protein slowed tumor growth. This project will approach HERV proteins as targets for drug discovery, with a focus on developing novel monoclonal antibodies to be used either to diagnose or treat ovarian cancer.

PADRES PEDAL THE CAUSE

Since 2013, Padres Pedal the Cause has brought San Diego's many diverse communities together to ride, run, walk and spin in a peer-to-peer fundraising challenge to end cancer. In the first post-pandemic event, 2200 participants returned to Petco Park for an incredible celebration of survivorship and record-breaking $3.2 million raised for cancer research.

To the survivors, fighters, family & friends, teams, sponsors and volunteers that continue to give 100%, thank you. With every mile, we are closer to cures.

PADRESPEDAL
THE CAUSE

A World Without Cancer

PADRES PEDAL THE CAUSE ADVISORY BOARD

Chris Tresse
Chairperson

Brett Chodorow
Scott Free
Suzanne Hatcher
Bill Hearne
Debra Jackson
Dale McIntosh
Chris Montgomery
Robert Murtfeldt
David Osias
Gene Smith
Tony Steigler
Ryan Thorvaldsen
Aubrey Valencia
Sally Welly
Shelley Zimmerman

$18.2 million
RAISED FOR RESEARCH THROUGH PADRES PEDAL THE CAUSE

2200
PARTICIPANTS IN 2022

126
TEAMS

26
LOCAL BUSINESSES THAT PARTNERED WITH PPTC IN 2022

300
VOLUNTEERS

PADRES PEDAL THE CAUSE

"We're riding for Stacey, but we're really riding for everyone." – Rick Valencia, Team Race for Stace

Team Race for Stace

My family has been participating in Pedal the Cause since its San Diego inception, and it has always been an important and worthy cause for us as we've watched how devastating the disease can be for those affected.

However, in November of 2021, we gained a whole new perspective on just how horrible and overwhelming it is when we learned that my mom, Stacey, was diagnosed with a rare and aggressive gynecologic cancer. It was and continues to be extremely difficult to watch her bravely battle against this cancer and all of the horrible side effects & complications that came along with it, but it gave us an even greater desire to do our part to help her and others. Padres Pedal the Cause has given us hope, a purpose, and a community to fully dive into through the devastation and trauma of the past year and a half. In fact, after we decided to make our Race for Stace team, we were made aware that proceeds from previous Pedal the Cause events were awarded to my mom's gynecologic oncologist for research in next generation sequencing that may someday benefit her. We're not sure if it's luck, fate or karma, but we do know we are so thankful that because of Pedal the Cause, she has this coincidental connection to her oncologist who was actually working to cure her even before they ever met. Additionally, our small but mighty Race for Stace team was able to raise $340k this past year which led to many grants, two of which specifically targeted ovarian cancer.

Because of grants like these from Pedal the Cause, we're even more optimistic that she will one day be cancer-free, and we will all live in a world without cancer. Until then though, we'll be doing everything we can to support Pedal the Cause and more research to make that happen. The Pedal family has become a part of our family, and we are so thankful for their abiding passion, support and guidance.

- Aubrey Valencia
Team Captain, Race for Stace

2022 TOP FUNDRAISERS

TOP 10 FUNDRAISING TEAMS	
Bill's Angels	$500,066
Race for Stace	$344,349
Bill's Team	$271,252
Beaumont's Cancer Crushers	$169,787
Cancer Curators (Powered by Holland)	$123,064
Kane's Crusaders – UCSD	$83,237
Team Bernstein for Rady Children's	$78,571
Team BD	$78,030
Team 19	$65,229
Team Illumina	$62,791

PODIUM	
Bill Koman	$129,385
Aubrey Valencia	$87,617
Rick Valencia	$86,213
John R McGrath Jr	$72,818
Julie Klaus	$68,091
Chris Tresse	$54,157
Wainwright Fishburn	$51,801
Amy Koman	$50,857
Lisa Altman	$50,000
Scott Hall	$47,163
Jeff Winslow	$46,075
Bill Holland	$40,000
Pia Jensen	$37,999
Connie Pittard	$35,426
Tony Stiegler	$25,326
Dave Heine	$25,189

MVP	
Andrew Valencia	$22,414
Brett Chodorow	$20,655
Jimmy Herbst	$18,185
Levent Alkibay	$17,052
Raghu Saripalli	$16,550
Ommid Asbaghi	$16,015
Genta Luddy	$15,570
Shamala Saripalli	$15,500
Pete Welly	$15,262
Steven Larky	$15,147
Scott Thurman	$14,620
Dale McIntosh	$13,596
Ryan Thorvaldsen	$12,502
Sally Welly	$12,422
Werner Kurn	$12,357
Mark Steele	$12,057
Scott Lippman	$11,550
Jeffrey Macelli	$11,254
Kat Kozlowski	$11,003
Gerrica Frankfurth	$10,639
Richard Whittington	$10,525
Sally Hood	$10,525
Gene Smith	$10,332
Leona Flores	$10,210
Andrea Pavan	$10,181
Hal Jacobs	$10,105
Steve Gregg	$10,105
Debby Jacobs	$10,100
Chris Kane	$10,040
Bill Gerhart	$10,000

2022 TOP FUNDRAISERS

YELLOW JERSEY	
Keenan Salvati	$9,687
Bryan Wang	$9,484
Denise Cavanagh	$9,099
Tim Lundquist	$9,010
Ben Reed	$8,985
Debra Jackson	$8,578
John Wilson	$8,470
Pat Welborn	$8,185
David Osias	$8,119
Mary Lippman	$8,035
Sheiva Brunst	$7,529
Luis Navazo	$7,427
Steven Shupper	$7,371
Tom Chamberlain	$7,000
Nicole Sweeney	$6,883
Mine Okano	$6,781
Scott Free	$6,715
Franci Free	$6,710
Jan Solomon	$6,667
Jerry Bohart	$6,631
Kevin Rainosek	$6,536
David Pavan	$6,477
Denise Hawkinson	$6,474
Misha Golynskiy	$6,452
Nick Mualim	$6,428
Jeff Venegas	$6,388
Mark Hoffman	$6,320
Kim Reed	$6,299
Juliann Ford	$6,271
Ash Roberts	$6,210
David Gatto	$6,182
Kim McKewon	$6,150
Stacey Pennington	$6,130
Mary Benirschke	$6,050
Jonathan Schwartz	$5,915
Neal Fischer	$5,859
Manoj Monga	$5,851
Ken Rolfes	$5,826
Ryan Bordelon	$5,817
Michael Militello	$5,793
Vickey Syage	$5,788
Joanne Marks	$5,730
David Crabb	$5,537
Suzy Weiser	$5,525
Christine Houser	$5,500
Charles Nagy	$5,355
Quynh Nguyen	$5,342
Brett Cook	$5,292
Kenna Anderes	$5,259
Glen Doshay	$5,250
Paul Dougherty	$5,250
Tom Seidler	$5,250
Joy Gorback	$5,116
Suzanne & Ian Hatcher	$5,110
Melissa Seipel Gerhart	$5,078
Karen Maegley	$5,061
Marc Hirschfield	$5,052
Lisette Polny	$5,035
Kate Deering	$5,033
Robert Anselmo	$5,005
Tammy Hershfield	$5,000
Donald Kearns	$5,000
Michael Marks	$5,000
Pete Schulte	$5,000
Jennifer Schwartz	$5,000
Katherine Chapin	$5,000
Jean Wickersham	$5,000
Edward Yragui	$5,000

In Memory of Dave Young

We honor the memory of Dave Young, a member of the Padres Pedal the Cause community and wonderful teammate on Kane's Crusaders since 2015. Dave passed in July of 2022 and is dearly missed.

SPONSORS

Thank you to the many generous local businesses and foundations that sponsor Padres Pedal the Cause. Because of you, 100% of every dollar raised funds life-saving cancer research.

CONCERT FOR CURES

On November 4th, the Curebound community came together to raise $3.1 million for cancer research at the inaugural benefit Concert for Cures. In a spectacular collaboration with the San Diego Symphony Orchestra, 15-time Grammy award winner Alicia Keys headlined the evening, giving an extraordinary performance and sharing heartfelt support for Curebound's mission. Amidst the beauty of the Rady Shell and the electric energy of the crowd on its feet, it was an unforgettable experience and the launch of a new signature event in San Diego.



CONCERT FOR CURES

HOST COMMITTEE

Amy Koman
Fernanda Whitworth
Event Co-Chairs

Sally & John Hood, PhD
Julie Tafel Klaus
Honorary Co-Chairs

Lisa & Steve Altman
Ommid Asbaghi & Levant Alkibay
Mei Barry
Mary & Rolf Benirschke
Cindy & Larry Bloch
Alex Brook & Shervin Mirhashemi
Patty & Marc Brutten
Tracy & Chuck Brymer
Katherine & Dane Chapin
Kat Cowling
Janet & Dennis Cruzan
Molly & Ted Eldredge
Margo Aura Emami, MD
Sally Fleck
Franci & Scott Free
Jen & Robert Gramins
Susie Nancarrow-Glenn & Scott Glenn
Fatima Grismer
Marie & Faheem Hasnain
Denise Hawkinson, PhD & Jim Herbst
Tammy & Larry Hershfield
Anne Daigle Ph.D. & Rich Heyman, PhD
Tracy & Trevor Hoffman
Sydney Holland
Debby & Hal Jacobs
Catriona Jamieson, MD, PhD & Sheldon Morris, MD
Julie & Erik Jorgensen
Marianne & Skip Kiil
Bill Koman
Jamie & Mark Kotsay
Laura Kreiss
Diane & Uri Kretowicz
Sophia Perez Lizano
Marilena & Greg Lucier
Genta Luddy
Joanne & Mick Marks
Christina Martinez
Haida & Ali Mojdehi
Sandy & Peter Mossy
Cheryl & Bill Naumann
Carolin Botzenhardt & Paul Noury
Saundra Pelletier
Connie & Dan Pittard
Theodora & Troy Polamalu
Joanie Polatchek O'Leary
Shirin & Kam Raiszadeh, MD
Kim & Ben Reed
Mae & Patrick Rhoten
Esther Rodriguez
Tammy & Cameron Rooke
Laleh Roudi
Dan Ryan
Shamala & Raghu Saripalli
Carrie & Richard Shen
Michelle & Rob Singh
Stephanie & Justin Smith
Shannon Sperlinga
Nicky & Mike Taylor
Stacey & Rick Valencia
Aubrey Valencia
Elyse & David Walker
Tracy Younger & Roger Schechter, MD

"San Diego has some of the best scientists and doctors in the world who work collaboratively together to create new therapies and new drugs. If cancer is going to be cured, it's going to happen here in San Diego."

– Julie Klaus, Honorary Co-Chair, Concert for Cures

SPONSORS

Thank you to the many generous corporate partners and local businesses that stepped forward as sponsors for the Concert for Cures in its inaugural year. We are tremendously grateful for your support and contributions to our community and mission.

ALEXANDRIA

charles SCHWAB · UC San Diego Health · Biocom California · JET AMG

corza · BOXER CAPITAL · Cooley · Sanford Burnham Prebys

CBRE San Diego Life Sciences Group · salk Where cures begin. · Rady Children's Hospital San Diego · Scripps Research · La Jolla Institute FOR IMMUNOLOGY

Siegel+Gale · TRACON PHARMA · ResMed · UC San Diego School of Medicine Neurological Surgery · MOSSY AUTOMOTIVE GROUP

Gensler · LYZZ CAPITAL · ERASCA · CUSHMAN & WAKEFIELD · ENDEAVOR BioMedicines

harvest small business finance, llc · direct systems support · WELLS FARGO The Private Bank · maravai LifeSciences FOUNDATION · DPR CONSTRUCTION

slalom · SCHUBACH AVIATION · JOHN MATTY CO. THE ART OF EXQUISITE JEWELRY · MELETIS & MUNSCH, LLP Certified Public Accountants · The Brutten Family Foundation

RANCH&COAST MAGAZINE · SAN DIEGO INTERNATIONAL FILM FESTIVAL · HAHN ENTERTAINMENT · The Good Feet Store America's Arch Support Experts · CJ La Jolla, CA · GB MAGAZINE

NEW WAYS TO CONNECT

In 2022, Curebound introduced several new opportunities for community engagement - building on existing programs and opening new channels to bring people and organizations together in collaboration. Through our partnership with Alexandria Real Estate, we established a series of networking events designed to bring members of the life science community together in new ways. We partnered with the San Diego International Film Festival to bring San Diego audiences together to experience the innovative work being done in cancer research today. With Curebound Kids, we are expanding our pediatric community program with Rady Children's Hospital to create special experiences for children and families fighting cancer.

San Diego International Film Festival Partnership
In October, we partnered with the San Diego International Film Festival to present the West Coast premiere of the film Of Medicine and Miracles. Following Dr. Carl June, the film chronicles the monumental task of curing cancer, as seen through the harrowing experiences of one young girl, her family, and a doctor on a mission. The power of storytelling through film helped bring members of the community together to share the critical importance of cancer research and the innovative methods of treatment that are being developed right now.

Curebound Connects
Collaboration is the cornerstone of our vision. This year, we launched Curebound Connects, the first of a new networking event series designed to bring members of the life science and biotech communities together for new opportunities to network and share ideas. In partnership with Alexandria Real Estate, we hosted special guest Ben Cravatt, PhD for a conversation on “Building Innovative Platform Companies and Medicines” with insight about the journey from scientific discovery to successful business. The September event established the first of many more Connects to come in 2023.

Curebound Kids
The Curebound Kids program is an evolution of Padres Pedal the Cause Superkids, creating special outings and experiences for the youngest members of our community who are battling cancer in partnership with the world class oncology team at Rady Children’s Hospital San Diego. Whether its riding with superheroes in the PPTC Kids Challenge or receiving special tickets to see Alicia Keys or cheering the Padres on to victory from the Owner’s Suite at Petco Park, the smiles on everyone’s faces are unforgettable. Curebound is proud and excited to continue partnering with Rady Children’s to support kids and families in need while raising awareness and critical funding to advance pediatric cancer research.

FOUNDERS FUND

In 2021, Curebound launched the Founders Fund to bring experts from San Diego's unique ecosystem of life sciences, research institutes and clinical settings together with the philanthropic community to ignite collaborative work for higher levels of discovery. Since then, the founding circle has grown substantially with 37 contributors totaling $23.5 million at the end of 2022. The Founders Fund campaign continues into 2023 as we move steadily toward our goal, which will provide substantial impact on the scope and breadth of research Curebound is able to fund.

FOUNDERS CIRCLE

We are grateful for the visionary leadership of our growing circle of founding investors, all of whom believe firmly that cures are possible and together, we can change the trajectory of cancer for future generations. Curebound is made possible through the support and extraordinary generosity of these individuals and organizations:

Founders
$1,000,000+
Alexandria Real Estate Equities, Inc.
Anonymous
Cindy & Larry Bloch
Boxer Capital
Wanda & Cam Garner
Denise Hawkinson & Jim Herbst
Anne Daigle & Rich Heyman
Sally & John Hood
Amy & Bill Koman
T. Denny Sanford
Fernanda Whitworth

Innovators
$500,000+
Roberta & Malin Burnham
Jennifer & Jay Levitt
Sandy & Peter Mossy
Shamala & Raghu Saripali
Michelle & Tom Wermers

Accelerators
$250,000+
The Michan Family
The Pardee Family Foundation

Leaders
$100,000+
Conrad Prebys Foundation
Cousins of Jay Levitt
Dickinson Family Foundation
Franci & Scott Free
Elaine Galinson & Herb Solomon
Sofia & Leon Kassel
Julie & Philip Mossy

Advocates
$50,000+
Joy & Don Ankeny
Nancy & Matt Browar
Tracy & Chuck Brymer
Jean Wickersham & Donald Kearns
Sheryl & Kirk Lester
Johanna Chanin & Randall Levitt
Kay Klass & Mark Levitt
Richard Moore
Marilyn & Mike Rosen
Melissa & Chris Tresse
Beth & Nathan Tross
Julie & Court Turner
Wong Family Fund

"Our family has supported Padres Pedal the Cause since its first ride in 2013 and we are very proud to have been part of its tremendous growth over the past ten years. Investing in the transformation to Curebound, and its unique capabilities to drive cancer research progress faster and further, is an investment in the future health of generations to come."

- Jim Herbst
Founder's Circle Member

FINANCIAL REPORT

2022 UNAUDITED FINANCIALS

REVENUE

Concert Ticket Sales	$2,740,972
Corporate Sponsorship	$595,146
Foundations	$140,000
Individual Contributions	$13,658,549
Participant Fundraising	$3,354,029
Partner Institutions	$300,000
TOTAL REVENUE	$20,788,697

EXPENSE

Event Expenses	$2,026,880
Operational Expenses	$2,542,451
Cancer Research Grant Distribution	$2,998,145
TOTAL EXPENSE	$7,567,476
NET INCOME	**$13,221,221**

REVENUE SOURCES



TOTAL REVENUE $20,788,697

REVENUE BY CAMPAIGN



TOTAL REVENUE $20,788,697

LEADERSHIP

Curebound would like to thank the members of the Board of Directors and Scientific Advisory Board for their leadership and dedication to our mission and larger vision of helping to create a world without cancer.

BOARD OF DIRECTORS

Bill Koman
Chairperson & Founder, Padres Pedal the Cause

Fernanda Whitworth
Founder, Immunotherapy Foundation

Don Ankeny
Finance Chair

Larry Bloch
Development Chair

Cheryl Anderson, PhD, MPH, MS
Malin Burnham
Mark Cafferty
Aaron Davis
Rich Heyman, Phd
John Hood, PhD
Catriona Jamieson, MD, PhD
Donald Kearns, MD
Anne Marbarger
Magda Marquet, PhD
Dan Ryan
Rob Singh
Chris Tresse
Court Turner, JD

SCIENTIFIC ADVISORY BOARD

John Hood, PhD
Chairperson

Paula Aristizabal, MD
Ezra Cohen, MD
Jon Edwards, PhD
Rich Heyman, PhD
Nancy Hong, PhD
Jeffery Kelly, PhD
Mitchell Kronenberg, PhD
Scott Lippman, MD
Monal Mehta, PhD
William Roberts, MD
Ze'ev Ronai, PhD
Reuben Shaw, PhD
Court Turner, JD

STAFF

Anne Marbarger
Chief Executive Officer

Karen Hooper
Chief Strategy & Implementation Officer

Heather Dean-Presnall
Strategic Philanthropy Officer

Liz DiGeronimo
Senior Manager, Padres Pedal the Cause

Shannon Gill
Director, Community Engagement

Kyle Harker
Operations Coordinator, Padres Pedal the Cause

Rahul Saripalli
Associate, Research & Operations

Kate Sinclair
Director, Communications & Creative

Kellie Sullivan
Senior Manager, Padres Pedal the Cause

Megan Waddell
Director, Padres Pedal the Cause

Adam Williams
Manager, Marketing & Communications

In Remembrance of Jay Levitt

On November 24, 2022, Jay Bradley Levitt left this world in the same way he lived his life: on his own terms, with a heart full of love, surrounded by those who cherished him most. An early member of Curebound's Board of Directors and Founders Fund Circle, Jay was a passionate advocate for cancer research who led by example, inspiring all who came into his orbit to think big, go further, and never give up. His memory is a blessing for all who were fortunate enough to know him and he is deeply missed.

OUR COMMITMENT

We remain steadfast in our commitment to translate community support and fundraising into research investments that produce better outcomes for patients. Curebound is ready to build on the momentum we have achieved together over the past twelve months and as we prepare to grow in our capabilities, outreach and impact, we are committed to the founding principles that continue to shape our larger vision: a world without cancer.

CURES

Curebound is founded with the deep-seated belief that cures are possible; that cancer is curable. With the knowledge that each small finding leads to a larger discovery and then one day, a breakthrough. Curebound will accelerate the speed at which we transform research into cures.

COLLABORATION

At Curebound, collaboration is central to everything we do. Our funding model creates collaboration across multiple disciplines among the top research institutions in San Diego. We provide early phase, follow-on and clinical trial funding to specialized research teams that bring together physician scientists, clinical researchers, and basic science researchers to work in partnership on specific challenges in cancer research.

COMMUNITY

In some way, this cause will touch all of our lives: every person, family and community. Curebound serves all of San Diego's diverse communities, united with one vision: cures in our lifetime. Through the power of collaboration and the spirit of community, we will ensure that the next generation doesn't hear the words "you have cancer" in the way we do today.